ASDERA, LLC
ASDERA generates and then out-licenses IP for pharmaceuticals to treat or prevent conditions without available disease-modifying drugs. To identify the targets and matching drugs/formulations from publicly available data others had found inconclusive, ASDERA uses a unique computational biostatistics approach that incorporates knowledge about genetics into the statistical method itself. ASDERA is currently seeking out-licensing opportunities in the areas of autism, carcinomas, neurodegeneration and cardiovascular diseases. The assets are protected by pending composition-of-matter and use patents and most are IND-ready for Phase 3 under 505(b)(2). Some of the assets are already under further development and available for licensing by partner companies.

Contact:
Knut Wittkowski, Ph.D., Sc.D.
Chief Executive Officer
knut@asdera.com
646-267-5688

Bezwada Biomedical, LLC
Bezwada Biomedical, LLC is a privately-held biomaterials company that develops, manufactures and markets innovative, proprietary, absorbable monomers and polymers for various biomedical applications and next-generation medical devices. We work with our customers to translate their demands into high quality products for a wide range of medical device and therapeutic applications in a cost-effective manner. Our expertise lies in the area of absorbable polyurethanes, absorbable polymers derived from functionalized natural products, drug molecules, amino acids, adhesion prevention barriers, absorbable drug eluting stent coatings, tissue adhesive and sealant, medical device coatings, drug delivery, drug device combination, absorbable implantable devices and tissue engineering.

Contact:
Raos Bezwada
President & Chief Executive Officer
rao@bezwadabiomedical.com
908-281-7529
BioSapien, Inc.
BioSapien, Inc. was founded in July 2018 as a C-Corporation in Delaware. BioSapien, Inc. is a biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology and anti-inflammatory therapies or indications. The company developed its product in October and has done the following: filed two provisional patents, conducted unofficial freedom to operate and has soft-commitments for $280K.

Contact:
Khatija Ali
Chief Executive Officer
kpa@biosapieninc.com
713-979-7791

Biotech Support Group, LLC
Located near Princeton, NJ, Biotech Support Group, LLC supplies research products used in proteomic analysis. Through the evaluation of these products and methods, we have discovered patent-pending biomarkers, called Stroma Liquid Biopsy™, which will greatly change the way cancer is detected, monitored and treated. We are seeking corporate partners and risk capital investment to commercialize these biomarkers.

Contact:
Matt Kuruc
Vice President, Business Development
mkuruc@biotechsupportgroup.com
732-274-2866

CuRAGE Therapeutics
CuRAGE Therapeutics is a virtual start-up biotechnology company formed in October 2018 and headquartered in Berwyn, PA with technology licensed from Columbia University. We are developing a humanized anti-RAGE (receptor for advanced glycation products) monoclonal antibody CR-3 that blocks the activity of an immuno-inflammatory pathway contributing to chronic disease development. Our lead indication is peripheral artery disease where CR-3 has demonstrated the ability to restore blood flow in both diabetic mouse and pig models of disease. Recent data indicate the potential for clinical use in several cancers, including ovarian, prostate and glioma. CR-3 has potential to reach $3-6 billion WW sales.

Contact:
Ihor Terleckyj, Ph.D.
Chief Executive Officer
i.terleckyj@verizon.net
610-647-2681
FLUIDDA, Inc.
FLUIDDA is the world leader in the field of Functional Respiratory Imaging (FRI) research and development. The company’s proprietary FRI technology offers pharmaceutical companies and healthcare providers a unique entry point into personalized medicine for patients suffering from respiratory diseases and sleep-related breathing disorders. Utilization of FRI in clinical practice creates significant added value to the current healthcare standard in the respiratory field.

Contact:
Benjamin Lavon
Business Developer
benjamin.lavon@fluidda.com
443-939-0098

Hillstream BioPharma, Inc.
Hillstream BioPharma is a development-stage company advancing improved therapies for patients with a focus on orphan oncologic diseases. Hillstream’s mission is to improve the safety and efficacy of existing drugs and/or proteins by encapsulating them in an enhanced injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures direct delivery into tumor cells; thereby preventing toxic-free drug circulation. Furthermore, encapsulation supports the slow and sustained release of the therapy and may also reduce dose frequency while maintaining efficacy. The novel formations to existing drugs allow Hillstream to build a strong patent estate and seek FDA Orphan Drug Designation for specific indications.

Contact:
Randy Milby
Chief Executive Officer
rmilby@hillstreambio.com
302-743-2995

In Vitro Diagnostic Solutions
In Vitro Diagnostic Solutions develops and manufactures point-of-care diagnostics devices for the diagnosis and monitoring of rare metabolic disorders.

Contact:
Robert Harper
President & Chief Executive Officer
robert@ivd.solutions
856-343-5098
LipidSense, Inc.
LipidSense, Inc. is a seed-stage biotech being spun out of Memorial Sloan Kettering Cancer Center. The company’s proprietary, non-invasive lipid-detection platform technology can streamline in vivo efficacy testing of drug candidates for important metabolic diseases (e.g., NASH and lysosomal storage disorders), as well as assaying for potential liver toxicity side effects in other drug development programs. The core technology is a nanosensor that when combined with a portable instrument functions as a highly sensitive optical reporter of lipid/fat content in the liver. LipidSense’s main business will be to produce and sell the reporter and instrument.

Contact:
Prakrit Jena, Ph.D.
Co-Founder, President & Chief Executive Officer
prakrit@lipidsense.com
347-464-2876

Klus Pharma
KLUS Pharma has been committed to the discovery and expansion of novel therapeutics for various diseases. We focus on developing innovative biologics, including monoclonal antibodies, multi-specific antibodies and ADC for the treatment of cancer, auto immune, cardiovascular and other severe diseases. Our platforms for antibody discovery, including hybridoma technology and phage display, create promising ways to expedite the movement of high quality biologic drugs from bench to market. We work closely with HCPs and KOLs to identify and assess multiple drug targets. Currently, over 10 therapeutic antibodies are in pre-clinical/clinical development.

Contact:
Laura Hong
President
laura.hong@kluspharma.com
609-662-1872

NOIGEL, LLC
NOIGEL, LLC is a New York-based company, established in 2010. Currently, scientific research is being performed at the Mechnikov Institute; one of the most established research centers in Eastern Europe. Our mission is to find new and innovative ways to treat MDR infections. Amongst the company’s expertise is utilizing synergistic combinations of FDA approved generic drugs and developing pharmaceutical compositions with new and unique applications. NOIGEL scientists have published extensive research studies supporting development of their pharmaceutical compositions.

Contact:
Ilya Kleyn, M.D.
Chief Medical Officer
drkleyn@nanoigel.com
917-554-5735
Nuritas
Nuritas is a drug discovery company that uses AI to accelerate the identification of bioactive peptides across multiple therapeutic areas, delivering candidate molecules in months with a high success rate (>60% predicted). This is due to our advanced AI platform for targeting, and unlocking those molecules — which are done in house (in silico and wet lab validation). Nuritas is the first company in the world to prove AI can take a healthcare product from concept to market, and did it in less than two years. We are currently addressing several indications in inflammation, diabetes, muscle health, anti-aging, hypertension and anti-microbials.

Contact:
Paul Rohricht
Chief Business Officer – Pharma
rohricht.paul@nuritas.com
215-802-8990

OTraces, Inc.
OTraces’ patented blood test technology merges math, physics and biology and thereby achieves 90% plus sensitivity and specificity for breast, prostate, ovarian, lung cancers and melanoma. Also, it can access cytokine activity in the tumor micro-environment (TME) that enables accurate monitoring of tumor progression (Active Surveillance) without biopsy. This prostate cancer test will be launched in the U.S. as a CLIA lab (LDT) test (not requiring FDA approval), soon after current Johns Hopkins validation trials under the direction of Dr. Kenneth Pienta have been completed — subject to a $2mm funding round currently underway.

Contact:
David Talbot
Senior Vice President, Business Development
Davidtalbot4@gmail.com
914-260-3505

RTM Vital Signs, LLC
RTM Vital Signs, LLC is a medical device start-up company at the forefront of the disruptive, transformative changes in healthcare from reactive and hospital-centered to proactive, predictive, preventive, data-based and patient-connected. RTM is developing proprietary, real-time, continuous vital sign monitoring systems for in-hospital and ambulatory respiratory and cardiac care. The RTM miniature, implantable cardiovascular monitoring system will be accurate enough for dosing medication and diagnosing an acute change in cardiac health, enabling increased knowledge and timely, predictive capability for prevention of adverse cardiac events.

Contact:
Jeffrey Joseph
Co-Founder & Chair, Scientific/Clinical Advisory Boards
Jeffrey.Joseph@RTMVitalSigns.com
215-620-9999
SAPHTx, Inc.
SAPHTx, Inc. is a seed-stage biotechnology company whose flagship product is a long-acting, first-in-class, injectable peptide-based drug, RetinGel, that attenuates new blood vessel growth in retina, useful for the treatment of wet age-related macular degeneration (wet AMD). RetinGel may help wet AMD patients by reducing dosing frequency 6X and cost 3X, compared to the standard-of-care, drugs such as Eylea.

Contact:
Biplap Sarkar, Ph.D.
Chief Executive Officer/NSF I-Corps Entrepreneurial Lead
sarkar@biplap-sarkar.com
281-794-6312

SFA Therapeutics, Inc.
SFA is focused on immuno-inflammatory diseases, including RA, psoriatic arthritis, lupus, IBD, psoriasis, liver and other cancers. Our small-molecule drugs derive from a novel immunomodulatory platform and are safer than MABs. Our lead products are in psoriasis and liver cancer (Hepatitis B, NASH & HCC). U.S. Patent 10,143,669 B2 was issued on December 4, 2018; to prevent Hepatitis B progression to HCC, a virus that affects 300M patients and causes 1M liver cancer deaths annually. FDA has approved entry into Phase 2 in psoriasis. Patents are pending in 25 diseases and recurrence of leukemia/lymphoma.

Contact:
Ira C. Spector, Ph.D.
Chief Executive Officer
iraspector@sfatherapeutics.com
267-584-1080

Solvuu, Inc.
Solvuu is a cloud-based data science platform to help life-scientists manage, analyze, explore and visualize genomics data. Our products enable customers to store petabytes of data securely and efficiently, integrate proprietary algorithms with the hundreds of open-source tools pre-packaged into our platform, run complex algorithms (AI/ML) at scale and explore data and job outputs through our visual analytics tools. Our AI-powered inference-engine infers a number of semantic properties of data at run-time, including file formats and industry-standard controlled vocabularies. An immutable data model provides versioning and an audit trail for regulatory compliance. We enhance the productivity of biologists, bioinformaticians and programmers.

Contact:
Ashish Agarwal
Founder & Chief Executive Officer
ashish@solvuu.com
203-848-7143
Tulex Pharmaceuticals
Tulex Pharmaceuticals was established in the fall of 2014 as a technology driven specialty pharmaceutical company by a team of highly experienced and proven scientists. Our focus is on developing and marketing innovative drug delivery technologies and complex generic drug products for oral administration. In the short time since our inception, Tulex has quickly expanded to a fully integrated FDA inspected cGMP facility capable of product development and commercial manufacturing of high quality drug products.

Contact:
James Lee, Ph.D.
Chief Executive Officer
jlee@tulexpharma.com
609-619-3098, ext. 205

Urigen Pharmaceuticals
Urigen Pharmaceuticals is a clinical-stage company leveraging innovative proprietary technology to develop best-in-class repurposed drugs for patients. We specialize in developing innovative products to ameliorate the cause and symptoms associated with urological ailments of the lower urinary tract, especially Interstitial Cystitis/Bladder Pain Syndrome (“BPS” or “IC/BPS”). Urigen is focused on reformulation of drugs to target these multi-billion-dollar market opportunities. We currently have one product candidate, URG101, in clinical development, and two product candidates, URG501 and URG801, in pre-clinical development.

Contact:
Dan Vickery
Chief Executive Officer
Dan.vickery@urigen.com
732-640-0160, ext. 204

Wellesley Pharmaceuticals, LLC
Wellesley’s focus is nocturia, the frequent need to urinate at night. Based on Phase 2 results, its patented drug is the most effective and safe treatment for nocturia by a wide margin. Nocturia causes insomnia, fatigue, depression, obesity and lower quality of life. It leads to high rates of heart disease, stroke, long-term brain damage and deadly falls — killing 1000’s per day. Rand’s recent published study estimated $44B in American productivity losses/year due to nocturia. Prescription specials sales should begin this summer. We are waiting to see which pharmaceutical giant wants to become the hero of the elderly.

Contact:
David A. Dill
President & Chief Executive Officer
ddill@wellessleypharma.com
215-493-0168